Last reviewed · How we verify

NCT04165525: CHEST

ConMed HelixAR™ ElectroSurgical Generator With Argon Beam Coagulation Technology Study

Status unknown NA Last updated 9 July 2021
What this trial tests

NA trial testing Ablation in Mastectomy; Lymphedema in 82 participants. Status unknown.

Timeline
26 May 2021
Primary endpoint
30 June 2022
30 December 2022

Quick facts

Lead sponsorSurgiQuest, Inc.
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment82
Start date26 May 2021
Primary completion30 June 2022
Estimated completion30 December 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

SurgiQuest, Inc.

Who can join

Adults 18 to 80, female only, with Mastectomy; Lymphedema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A PROSPECTIVE, RANDOMIZED, CONTROLLED STUDY TO EVALUATE DEVICE EFFICACY BETWEEN THE HELIXAR ELECTROSURGICAL GENERATOR (HEG) VS. CONVENTIONAL ELECTROSURGICAL COAGULATION (CEC) FOR CUTTING AND/OR COAGULATION OF TISSUE DURING MASTECTOMY PROCEDURES

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ablation

Trials testing the same drug.

Other recruiting trials for Mastectomy; Lymphedema

Currently open trials in the same condition.

Other SurgiQuest, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04165525.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing